Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Raia Drogasil S.A. (RADL3.SA)
BRL18.62
+0.02 (+0.11%)
BR SAO Consumer Defensive Household & Personal Products
Address
Av. Corifeu de Azevedo Marques, 3097 05339-900
São Paulo, SP, BR
São Paulo, SP, BR
CEO
Renato Raduan
Website
rdsaude.com.br
IPO
2000-01-06
ISIN BRRADLACNOR0
Also trades on
B3 S.A. · RADL3.SA (BRL)
Other OTC · RADLY (USD)
Description
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
BRL18.62
+0.02 (+0.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.02
Float Shares
1.31B
Free Float %
75.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.68% | -4.44% | -14.15% | -22.68% | -10.50% | -13.68% | +27.33% | -22.07% | -12.23% | +101.48% | +833.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
18.62
DCF (Unlevered)
51.88
+178.6%
DCF (Levered)
29.57
+58.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
73% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.50
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Household & Personal Products: +3.3%+13.9% ★ Q1'26: +5.1% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%+6.9% Q1'26: -5.2% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+2.3% Q1'26: +4.8% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+6.0% Q1'26: +4.0% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+15.1% ★ Q1'26: +11.0% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%+0.2% Q1'26: +2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×1.90× Q1'26: 2.20× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 7 EPS Ana. |
Dec 2027 10 Rev. Ana. 6 EPS Ana. |
Dec 2028 9 Rev. Ana. 5 EPS Ana. |
Dec 2029 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.90B
est: 8.88B (+0.3%)
|
11.26B
est: 11.28B (-0.2%)
|
13.21B
est: 13.39B (-1.3%)
|
14.80B
est: 14.78B (+0.2%)
|
17.57B
est: 17.46B (+0.6%)
|
20.07B
est: 20.07B (0.0%)
|
24.13B
est: 24.11B (+0.1%)
|
29.07B
est: 29.14B (-0.2%)
|
33.97B
est: 36.39B (-6.6%)
|
38.86B
est: 39.11B (-0.6%)
|
44.25B
est: 44.35B (-0.2%)
|
50.02B
48.92B – 51.15B
+12.8% YoY
|
56.46B
54.15B – 58.81B
+12.9% YoY
|
62.92B
62.91B – 62.93B
+11.4% YoY
|
71.51B
69.93B – 73.12B
+13.7% YoY
|
| EBITDA |
697.95M
est: 811.88M (-14.0%)
|
913.75M
est: 1.03B (-11.4%)
|
1.09B
est: 1.23B (-11.0%)
|
1.11B
est: 1.35B (-17.7%)
|
2.18B
est: 1.60B (+36.3%)
|
2.08B
est: 1.84B (+13.1%)
|
2.60B
est: 2.21B (+17.8%)
|
2.45B
est: 2.67B (-8.0%)
|
2.75B
est: 3.34B (-17.6%)
|
3.14B
est: 3.59B (-12.5%)
|
4.65B
est: 4.07B (+14.2%)
|
4.59B
4.49B – 4.69B
+12.8% YoY
|
5.18B
4.97B – 5.40B
+12.9% YoY
|
5.78B
5.77B – 5.78B
+11.4% YoY
|
6.56B
6.42B – 6.71B
+13.7% YoY
|
| EBIT |
470.25M
est: 486.57M (-3.4%)
|
652.91M
est: 618.39M (+5.6%)
|
754.25M
est: 734.17M (+2.7%)
|
697.33M
est: 810.02M (-13.9%)
|
1.07B
est: 957.26M (+12.2%)
|
899.74M
est: 1.10B (-18.2%)
|
1.30B
est: 1.32B (-1.4%)
|
1.75B
est: 1.60B (+9.7%)
|
1.95B
est: 2.31B (-15.5%)
|
2.23B
est: 2.49B (-10.4%)
|
2.64B
est: 2.82B (-6.5%)
|
3.18B
3.11B – 3.25B
+12.8% YoY
|
3.59B
3.44B – 3.74B
+12.9% YoY
|
4.00B
4.00B – 4.00B
+11.4% YoY
|
4.55B
4.45B – 4.65B
+13.7% YoY
|
| Net Income |
340.21M
est: 355.99M (-4.4%)
|
447.69M
est: 491.65M (-8.9%)
|
511.16M
est: 527.81M (-3.2%)
|
502.45M
est: 505.19M (-0.5%)
|
772.24M
est: 593.91M (+30.0%)
|
484.44M
est: 555.46M (-12.8%)
|
751.93M
est: 813.29M (-7.5%)
|
996.11M
est: 918.20M (+8.5%)
|
1.05B
est: 1.04B (+1.5%)
|
1.20B
est: 1.14B (+4.6%)
|
1.30B
est: 1.30B (-0.5%)
|
1.73B
1.56B – 1.76B
+32.7% YoY
|
2.19B
1.88B – 2.20B
+26.4% YoY
|
2.47B
2.34B – 2.60B
+13.2% YoY
|
2.89B
2.80B – 2.97B
+16.6% YoY
|
| SGA |
1.98B
est: 2.15B (-8.0%)
|
2.52B
est: 2.73B (-7.8%)
|
3.20B
est: 3.24B (-1.4%)
|
3.66B
est: 3.58B (+2.5%)
|
4.29B
est: 4.23B (+1.5%)
|
4.94B
est: 4.86B (+1.6%)
|
5.88B
est: 5.84B (+0.7%)
|
7.06B
est: 7.05B (+0.1%)
|
8.19B
est: 8.38B (-2.2%)
|
9.19B
est: 9.01B (+2.1%)
|
8.28B
est: 10.21B (-18.9%)
|
11.52B
11.26B – 11.78B
+12.8% YoY
|
13.00B
12.47B – 13.54B
+12.9% YoY
|
14.49B
14.48B – 14.49B
+11.4% YoY
|
16.47B
16.10B – 16.84B
+13.7% YoY
|
| EPS |
0.20
est: 0.22 (-7.0%)
|
0.26
est: 0.30 (-12.5%)
|
0.30
est: 0.32 (-5.9%)
|
0.29
est: 0.31 (-5.0%)
|
0.45
est: 0.36 (+25.4%)
|
0.28
est: 0.34 (-16.6%)
|
0.44
est: 0.49 (-10.5%)
|
0.58
est: 0.55 (+4.5%)
|
0.65
est: 0.62 (+5.2%)
|
0.73
est: 0.69 (+5.8%)
|
0.79
est: 0.77 (+2.6%)
|
0.99
0.94 – 1.06
+29.1% YoY
|
1.24
1.14 – 1.33
+24.8% YoY
|
1.48
1.41 – 1.57
+19.3% YoY
|
1.74
1.69 – 1.79
+17.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.25B
OE per share TTM
1.32
Owner's Yield
6.64%
Maintenance CapEx ratio
100.11%
Maint CapEx / Avg PPE
19.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 154 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - Brazil Active ETF BRAZ | 2.39% | 239.9K | 0.75% |
| 2 | iShares MSCI Brazil ETF EWZ | 1.05% | 96.44M | 0.59% |
| 3 | Franklin FTSE Brazil ETF FLBR | 1.03% | 5.61M | 0.19% |
| 4 | Franklin FTSE Brazil UCITS ETF FLXB.L | 1.03% | 1.64M | 0.19% |
| 5 | iShares MSCI Brazil UCITS ETF USD (Dist) IDBZ.L | 0.98% | 4.97M | 0.74% |
| 6 | iShares MSCI Brazil UCITS ETF (DE) 4BRZ.DE | 0.98% | 46.22M | 0.27% |
| 7 | Xtrackers MSCI Brazil UCITS ETF 1C XMBD.L | 0.93% | 2.42M | 0.25% |
| 8 | Franklin FTSE Latin America ETF FLLA | 0.61% | 662.0K | 0.19% |
| 9 | iShares MSCI EM Latin America UCITS ETF DLTM.L | 0.51% | 10.12M | 0.20% |
| 10 | iShares Ageing Population UCITS ETF AGED.L | 0.42% | 3.67M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
35.7K
Shares Outstanding
1.75B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Afonso Celso Florentino de Oliveira | Director of Controllership | — | — |
| Antonio Carlos Coelho | Vice President of Finance & Administrative and Member of Executive Board | — | male |
| Bruno Wright Pipponzi | Vice President of Health Business & Member of Executive Board | — | male |
| Celso Pissi Filho | Accountant & Technical Manager | — | — |
| Erika Petri | Vice President of People & Sustainability | — | — |
| Fernando Kozel Varela | Vice President of Digital Transformation & Member of Executive Board | — | male |
| Flavio Fogaca | Director of IR, Corporate Affairs & Strategy | — | — |
| Juliana Lopes Marques Paixao | Commercial Vice President | — | — |
| Marcello De Zagottis | Chief Operating Officer & Member of Executive Board | — | male |
| Melissa Teixeira Cabral | Vice President of Pharmacy Operations | — | female |
| Renato Cepollina Raduan | Chief Executive Officer & Member of Executive Board | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RADL3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
